| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695374 | Gynecologic Oncology | 2017 | 7 Pages |
Abstract
In this post hoc subset analysis of patients with uLMS who had received prior anthracycline therapy, trabectedin treatment resulted in significantly longer PFS versus dacarbazine, with an acceptable safety profile. There was no difference in OS.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Martee L. Hensley, Shreyaskumar R. Patel, Margaret von Mehren, Kristen Ganjoo, Robin L. Jones, Arthur Staddon, Daniel Rushing, Mohammed Milhem, Bradley Monk, George Wang, Sharon McCarthy, Roland E. Knoblauch, Trilok V. Parekh, Robert G. Maki,